健康元：2024年第三季度报告(英文版)
Stock Code: 600380 Stock Short Name: 健康元
Joincare Pharmaceutical Group Industry Co., Ltd.
2024 Third Quarterly Report
The Board of Directors and all Directors of the Company hereby warrant that thereare no false representations, misleading statements or material omissions contained inthis announcement and accept legal responsibility for the truthfulness, accuracy andcompleteness of the contents hereof.
IMPORTANT NOTICE:
? The Board of Directors, the Board of Supervisors and Directors, Supervisors and senior managementof the Company hereby warrant the truthfulness, accuracy and completeness of the contents of thisquarterly report, and that there are no false representations, misleading statements or materialomissions contained herein, and severally and jointly accept legal responsibility.
? The person-in-charge of the Company, the person-in-charge of accounting work and the person-in-charge of the accounting department (the head of the accounting department) hereby warrant thetruthfulness, accuracy and completeness of the financial information contained in this quarterly report.
? Whether the third quarterly financial statements have been audited.
□Yes √No
I. MAJOR FINANCIAL DATA(I) Major Accounting Data and Financial Indicators
Unit: Yuan Currency: RMB
| Item | For the Reporting Period | YoY change (%) | From the beginning of the year to the end of the Reporting Period | YoY change (%) |
| Revenues | 3,664,194,805.57 | -6.80 | 11,898,828,905.02 | -5.95 |
| Net profit attributable to Shareholders of the listed company | 335,135,597.05 | 24.95 | 1,111,560,063.92 | 2.58 |
| Net profit attributable to Shareholders of the listed company after deduction of extraordinary gain and loss | 311,474,846.35 | 16.45 | 1,073,381,416.07 | 2.30 |
| Net cash flow from operating activities | N/A | N/A | 2,613,605,501.06 | 6.25 |
| Basic earnings per share (RMB/share) | 0.18 | 26.01 | 0.59 | 4.63 |
| Diluted earnings per share (RMB/share) | 0.18 | 26.79 | 0.59 | 4.97 |
| Weighted average return on net assets (%) | 2.32 | Increased by 0.39 percentage points | 7.82 | Decreased by 0.40 percentage points |
| As at the end of the Reporting Period | As at the end of the previous year | Change in the ending amount of the Reporting Period to that of the previous year (%) | ||
| Total assets | 36,172,500,281.87 | 36,358,126,258.82 | -0.51 | |
| Net assets attributable to Shareholders of the listed company | 14,487,774,610.56 | 13,755,901,924.06 | 5.32 | |
Notes: 1. The “Reporting Period” represents the 3-month period from the beginning to the end of thisquarter, the same below.
2. From January to September 2024, the Company’s Chemical pharmaceuticals achieved revenues ofRMB5,879 million, representing a year-on-year decrease of 10.55%. Among them, revenues fromgonadotropic hormones products reached RMB2,308 million, representing a year-on-year increase of
5.46%; revenues from gastroenterology products reached RMB1,854 million, representing a year-on-yeardecrease of 18.66%; revenues from respiratory formulation products reached RMB799 million,representing a year-on-year decrease of 28.18%; revenues from psychiatry products reached RMB443million, representing a year-on-year increase of 3.11%; and revenues from anti-infective products reachedRMB322 million, representing a year-on-year decrease of 19.46%. Revenues from APIs and intermediatesamounted to RMB3,857 million, representing a year-on-year decrease of 2.83%. Revenues fromtraditional Chinese medicine (TCM) formulations were RMB1,084 million, representing a year-on-yeardecrease of 16.06%. Revenues from diagnostic reagents and equipment were RMB566 million,representing a year-on-year increase of 21.03%. Revenues from health care products amounted toRMB262 million, representing a year-on-year increase of 97.67%, while revenues from biologicalproducts reached RMB131 million, representing a year-on-year increase of 15.98%.
3. From January to September 2024, the Company realized net profit attributable to shareholders ofthe parent of RMB1,112 million, of which Joincare (excluding Livzon Group and Livzon MAB) realizednet profit attributable to shareholders of the parent of approximately RMB479 million, representing a YoYdecrease of approximately 21.65%, and the impact of Livzon MAB on the net profit attributable toshareholders of the parent was approximately negative RMB164 million.
(II) Items and Amounts of Extraordinary Gains and Losses
√Applicable □N/A
Unit: Yuan Currency: RMB
| Item | For the Reporting Period | From the beginning of the year to the end of the Reporting Period |
| Gains and losses on disposal of non-current assets (including the reversal of previously recognized asset impairment provisions) | -303,991.87 | -380,432.23 |
| Government grants recognized in profit or loss for the current period (excluding government grants that are closely related to the business of the Company and are provided in fixed amount or quantity continuously according to the applicable polices and standards of the country). | 44,861,228.31 | 97,182,195.46 |
| Excluding effective hedging activities related to the company's ordinary operating business, this refers to gains and losses arising from changes in the fair value of financial assets and financial liabilities held by non-financial enterprises, as well as gains and losses from the disposal of financial assets and financial liabilities. | 15,453,330.81 | -1,320,002.12 |
| Other non-operating income and expenses excluding the above items | -8,178,945.07 | -13,068,229.51 |
| Less: Effect of income tax | 6,413,048.49 | 12,226,800.99 |
| Effect of minority equity (after tax) | 21,757,822.99 | 32,008,082.76 |
| Total | 23,660,750.70 | 38,178,647.85 |
For the items not listed in the “Explanatory Announcement No.1 for Public Company InformationDisclosures-Extraordinary Gains or Losses” that the company identifies as non-recurring gains and losses,especially those with significant amounts, as well as the extraordinary gain or loss items as illustrated inthe “Explanatory Announcement No.1 for Public Company Information Disclosures-Extraordinary Gainsor Losses” which has been defined as its recurring gain or loss items, the reasons for such classificationshould be explained.
□Applicable √N/A
(III) Changes in Major Accounting Data and Financial Indicators and Reasons Thereof
□Applicable √N/A
(IV) Material Changes in Other Items in Financial Statements and Financial Indicators and ReasonsThereof
Unit: Yuan Currency: RMB
| Balance Sheet | 30 September 2024 | 31 December 2023 | Change in proportion （%） | Main Reason |
| Other receivables | 85,854,197.50 | 46,010,624.61 | 86.60 | Mainly due to the stock options exercised by employees of the subsidiary Livzon Group this period have not yet received the corresponding payment. |
| Non-current assets due within one year | 650,845,317.12 | 406,376,425.44 | 60.16 | Mainly due to an increase in time deposits maturing within one year. |
| Other current assets | 294,526,056.46 | 77,402,185.01 | 280.51 | Mainly due to new short-term cash management activities. |
| Other non-current financial assets | 1,399,815,097.39 | 957,224,255.77 | 46.24 | Mainly due to new cash management activities. |
| Financial liabilities held for trading | 267,731.76 | 86,817.12 | 208.39 | Mainly due to changes in the fair value of forward foreign exchange contracts. |
| Contract liabilities | 98,823,153.11 | 159,082,637.65 | -37.88 | Mainly due to the recognition of revenue from contract advances that met the criteria for revenue recognition during this period. |
| Taxes payable | 271,059,346.85 | 410,202,854.09 | -33.92 | Mainly due to a decrease in corporate income tax payable this period. |
| Non-current liabilities due within one year | 1,930,684,639.47 | 718,564,144.31 | 168.69 | Mainly due to the transfer of long-term loans maturing within one year. |
| Other current liabilities | 12,832,993.44 | 51,087,001.83 | -74.88 | Mainly due to a decrease in estimated refund liabilities. |
| Long-term loans | 1,372,606,325.72 | 3,122,273,278.99 | -56.04 | Mainly due to the reclassification of long-term loans maturing within one year to current liabilities. |
| Other comprehensive income | -65,054,363.34 | -12,246,131.22 | N/A | Mainly due to changes in the fair value of other equity instruments and fluctuations in exchange rates, resulting in variations in foreign currency translation adjustments. |
| Statement of Income | January to September 2024 | January to September 2023 | Change in proportion （%） | Main Reason |
| Financial expenses | -105,969,421.63 | -314,423,140.18 | N/A | Mainly due to a decrease in interest income from deposits and fluctuations in foreign exchange gains and losses. |
| Gains from changes in fair value | -5,736,443.62 | -46,003,628.22 | N/A | Mainly due to fluctuations in the market value of held securities investments. |
| Losses of credit impairment | -797,210.83 | -17,737,505.85 | N/A | Mainly due to a decrease in long-aged accounts receivable, leading to a corresponding reduction in expected credit impairment losses. |
| Impairment loss of assets | -370,399.04 | -200,478.63 | N/A | Mainly due to an increase in losses from the disposal of fixed assets. |
| Other comprehensive income, net of tax | -86,688,069.37 | -22,658,520.87 | N/A | Mainly due to changes in the fair value of other equity instrument investments and fluctuations in exchange |
| rates, resulting in variations in foreign currency translation adjustments. | ||||
| Cash Flow Statement | January to September 2024 | January to September 2023 | Change in proportion （%） | Main Reason |
| Net cash flows from investing activities | -1,183,961,052.92 | -675,752,976.46 | N/A | Mainly due to a higher amount of investment payments made during the current period. |
II. SHAREHOLDERS(I) Total Number of Holders of Ordinary Shares and Number of Holders of Preferred Shares with RestoredVoting Rights and Shareholdings of Top 10 Shareholders
Unit: shares
| Total number of holders of ordinary shares as of the end of the Reporting Period | 76,823 | Total number of holders of preferred shares with restored voting rights as of the end of the Reporting Period (if any) | 0 | ||||||
| Shareholdings of the top 10 shareholders （excluding shares lent through refinancing business） | |||||||||
| Name of shareholder | Nature of shareholder | Number of shares held | Percentage (%) | Number of shares held with selling restrictions | Pledge, mark or lock-up | ||||
| Share status | Number | ||||||||
| Shenzhen Baiyeyuan Investment Co., Ltd. (深圳市百业源投资有限公司) | Domestic non-state-owned legal person | 895,653,653 | 47.79 | 0 | Pledge | 55,679,725 | |||
| Hong Kong Securities Clearing Company Limited | Unknown | 97,098,746 | 5.18 | 0 | Unknown | ||||
| Might Seasons Limited | Foreign legal person | 35,929,699 | 1.92 | 0 | Unknown | ||||
| Agriculture Bank of China Limited-CSI 500 Exchange Traded Index Securities Invest Fund | Unknown | 20,006,912 | 1.07 | 0 | Unknown | ||||
| Perseverance Asset Management L.L.P–Gaoyi Xiaofeng No. 2 Zhixin Fund | Unknown | 14,364,600 | 0.77 | 0 | Unknown | ||||
| China Foreign Economy and Trade Trust Co., Ltd.–Foreign Trust–Gaoyi Xiaofeng Hongyuan Collection Fund Trust Plan | Unknown | 13,130,100 | 0.70 | 0 | Unknown | ||||
| Rui Life Insurance Co., Ltd. - Own fund | Unknown | 12,729,218 | 0.68 | 0 | Unknown | ||||
| Abu Dhabi Investment Authority | Foreign legal person | 12,502,378 | 0.67 | 0 | Unknown | ||||
| CPIC Fund -China Pacific Life Insurance Co., Ltd. -with-profit insurance-CPIC Fund China Pacific Life Equity Relative Income (Guaranteed Dividend) single assets management plan | Unknown | 10,170,000 | 0.54 | 0 | Unknown | ||||
| Bank of Shanghai Co., Ltd.－Yinhua CSI Innovative Drug Industry Trading Open-end Index Securities Investment Fund | Unknown | 9,836,796 | 0.52 | 0 | Unknown | ||||
| Shareholdings of the top 10 shareholders without selling restrictions （excluding shares lent through refinancing business） | |||||||||
| Name of shareholder | Number of tradable shares held without selling restrictions | Class and number of shares | |||||||
| Class of shares | Number | ||||||||
| Shenzhen Baiyeyuan Investment Co., Ltd. (深圳市百业源投资有限公司) | 895,653,653 | Ordinary shares denominated in Renminbi | 895,653,653 |
| Hong Kong Securities Clearing Company Limited | 97,098,746 | Ordinary shares denominated in Renminbi | 97,098,746 |
| Might Seasons Limited | 35,929,699 | Ordinary shares denominated in Renminbi | 35,929,699 |
| Agriculture Bank of China Limited-CSI 500 Exchange Traded Index Securities Invest Fund | 20,006,912 | Ordinary shares denominated in Renminbi | 20,006,912 |
| Perseverance Asset Management L.L.P–Gaoyi Xiaofeng No. 2 Zhixin Fund | 14,364,600 | Ordinary shares denominated in Renminbi | 14,364,600 |
| China Foreign Economy and Trade Trust Co., Ltd.–Foreign Trust–Gaoyi Xiaofeng Hongyuan Collection Fund Trust Plan | 13,130,100 | Ordinary shares denominated in Renminbi | 13,130,100 |
| Rui Life Insurance Co., Ltd. - Own fund | 12,729,218 | Ordinary shares denominated in Renminbi | 12,729,218 |
| Abu Dhabi Investment Authority | 12,502,378 | Ordinary shares denominated in Renminbi | 12,502,378 |
| CPIC Fund -China Pacific Life Insurance Co., Ltd. -with-profit insurance-CPIC Fund China Pacific Life Equity Relative Income (Guaranteed Dividend) single assets management plan | 10,170,000 | Ordinary shares denominated in Renminbi | 10,170,000 |
| Bank of Shanghai Co., Ltd.－Yinhua CSI Innovative Drug Industry Trading Open-end Index Securities Investment Fund | 9,836,796 | Ordinary shares denominated in Renminbi | 9,836,796 |
| Description of connection or acting-in-concert relationship of the above shareholders | There was no connection or acting-in-concert relationship between Shenzhen Baiyeyuan Investment Co., Ltd., a controlling shareholder of the Company, and other shareholders; whether there is connection or acting-in-concert relationship among other shareholders is unknown. | ||
| Description of the participation of the top 10 shareholders and the top 10 shareholders without selling restrictions in margin financing and securities lending and refinancing business (if any) | N/A | ||
Participation of shareholders holding over 5%, the top 10 shareholders, and the top 10 shareholderswithout selling restriction in securities lending transactions of refinancing business
√Applicable □N/A
Unit: shares
| Participation of shareholders holding over 5%, the top 10 shareholders, and the top 10 shareholders without selling restriction in securities lending transactions of refinancing business | ||||||||
| Name of shareholder (Full name) | Number of shares held in ordinary and credit accounts at the beginning of the Period | Number of shares lent through refinancing business and not yet returned at the beginning of the Period | Number of shares held in ordinary and credit accounts at the end of the Period | Number of shares lent through refinancing business and not yet returned at the end of the Period | ||||
| Total number | Proportion (%) | Total number | Proportion (%) | Total number | Proportion (%) | Total number | Proportion (%) | |
| Agriculture Bank of China Limited-CSI 500 Exchange Traded Index Securities Invest Fund | 5,055,774 | 0.27 | 1,509,200 | 0.08 | 20,006,912 | 1.07 | 0 | 0.00 |
| Bank of Shanghai Co., Ltd.－Yinhua CSI Innovative Drug Industry Trading Open-end Index Securities Investment Fund | 8,458,496 | 0.45 | 10,000 | 0.001 | 9,836,796 | 0.52 | 0 | 0.00 |
Changes in the top 10 shareholders and the top 10 shareholders without selling restriction due to securitieslending/returning transactions of refinancing business compared to the previous period
□Applicable √N/A
III. OTHER REMINDERSOther important information regarding the Company’s operations during the Reporting Period to whichinvestors should be reminded to pay attention.
□Applicable √N/A
IV. QUARTERLY FINANCIAL STATEMENTS(I) Audit Opinion
□Applicable √N/A
(II) Financial Statements
Consolidated Balance Sheet
30 September 2024Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | 30 September 2024 | 31 December 2023 |
| Current assets: | ||
| Monetary funds | 14,594,801,258.03 | 15,691,888,314.83 |
| Financial assets held for trading | 77,343,625.25 | 82,899,154.24 |
| Notes receivable | 1,840,201,163.60 | 1,941,200,568.00 |
| Accounts receivable | 2,672,357,170.76 | 2,692,941,866.24 |
| Receivables financing | ||
| Prepayments | 306,162,056.96 | 280,102,860.94 |
| Other receivables | 85,854,197.50 | 46,010,624.61 |
| In which: Interests receivable | ||
| Dividends receivable | ||
| Inventories | 2,605,104,655.82 | 2,655,808,391.09 |
| Contract assets | ||
| Assets held-for-sale | ||
| Non-current assets due within one year | 650,845,317.12 | 406,376,425.44 |
| Other current assets | 294,526,056.46 | 77,402,185.01 |
| Total current assets | 23,127,195,501.50 | 23,874,630,390.40 |
| Non-current assets: | ||
| Debt investment | ||
| Other debt investment | ||
| Long-term receivables | ||
| Long-term equity investment | 1,467,317,916.58 | 1,411,036,353.95 |
| Other equity instrument investments | 1,066,048,054.16 | 1,155,283,408.36 |
| Other non-current financial assets | ||
| Investment properties | 16,327,550.42 | 16,958,213.00 |
| Fixed assets | 5,638,056,264.70 | 5,664,352,555.97 |
| Construction in progress | 662,547,623.17 | 531,059,118.06 |
| Productive biological assets | ||
| Oil and gas assets | ||
| Right-of-use assets | 28,190,760.95 | 36,233,067.49 |
| Intangible assets | 731,856,861.97 | 683,337,333.73 |
| Development expenditures | 461,930,852.53 | 483,494,487.17 |
| Goodwill | 636,339,503.82 | 636,339,503.82 |
| Long-term deferred expenses | 317,024,375.10 | 328,642,740.95 |
| Deferred income tax assets | 619,849,919.58 | 579,534,830.15 |
| Other non-current assets | 1,399,815,097.39 | 957,224,255.77 |
| Total non-current assets | 13,045,304,780.37 | 12,483,495,868.42 |
| Total assets | 36,172,500,281.87 | 36,358,126,258.82 |
| Current liabilities: | ||
| Short-term loans | 2,050,000,000.00 | 2,076,159,347.22 |
| Financial liabilities held for trading | 267,731.76 | 86,817.12 |
| Notes payable | 1,433,953,960.81 | 1,469,148,287.38 |
| Accounts payable | 832,051,361.15 | 894,286,243.28 |
| Receipts in advance | ||
| Contract liabilities | 98,823,153.11 | 159,082,637.65 |
| Employee benefits payable | 382,925,497.74 | 399,466,473.91 |
| Taxes payable | 271,059,346.85 | 410,202,854.09 |
| Other payables | 3,553,679,167.04 | 3,682,604,038.73 |
| In which: Interests payable | ||
| Dividends payable | 10,022,086.38 | 12,478,280.13 |
| Liabilities held-for-sale | ||
| Non-current liabilities due within one year | 1,930,684,639.47 | 718,564,144.31 |
| Other current liabilities | 12,832,993.44 | 51,087,001.83 |
| Total current liabilities | 10,566,277,851.37 | 9,860,687,845.52 |
| Non-current liabilities: | ||
| Long-term loans | 1,372,606,325.72 | 3,122,273,278.99 |
| Bonds payable | ||
| Lease liabilities | 12,031,618.67 | 15,422,948.41 |
| Long-term payables | ||
| Long-term payroll payable | ||
| Estimated liabilities | ||
| Deferred income | 334,243,550.30 | 370,179,550.82 |
| Deferred income tax liabilities | 252,362,201.09 | 260,032,144.44 |
| Other non-current liabilities | 90,000,000.00 | 90,000,000.00 |
| Total non-current liabilities | 2,061,243,695.78 | 3,857,907,922.66 |
| Total liabilities | 12,627,521,547.15 | 13,718,595,768.18 |
| Owner's equity (or shareholder's equity): | ||
| Paid-in capital | 1,874,200,420.00 | 1,865,523,807.00 |
| Other equity instruments | ||
| In which: Preferred shares | ||
| Perpetual debts | ||
| Capital reserve | 1,592,054,957.78 | 1,601,720,087.71 |
| Less: Treasury shares | ||
| Other comprehensive income | -65,054,363.34 | -12,246,131.22 |
| Special reserve | ||
| Surplus reserve | 859,046,203.77 | 859,046,203.77 |
| Undistributed profits | 10,227,527,392.35 | 9,441,857,956.80 |
| Total owner's equity (or shareholder's equity) attributable to the parent | 14,487,774,610.56 | 13,755,901,924.06 |
| Minority shareholder's equity | 9,057,204,124.16 | 8,883,628,566.58 |
| Total owner's equity (or shareholder's equity) | 23,544,978,734.72 | 22,639,530,490.64 |
| Total liabilities and owner's equity (or shareholder's equity) | 36,172,500,281.87 | 36,358,126,258.82 |
Person-in-charge of theCompany: Zhu Baoguo
Person-in-charge of theCompany's accounting work:
Qiu Qingfeng
Person-in-charge of theaccounting department:
Guo Chenlu
Consolidated Income StatementFrom January to September, 2024Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | First three quarters (January to September) for 2024 | First three quarters (January to September) for 2023 |
| I. Total revenues | 11,898,828,905.02 | 12,651,257,386.44 |
| In which: Operating revenues | 11,898,828,905.02 | 12,651,257,386.44 |
| II. Total operating costs | 9,121,682,123.61 | 9,992,088,727.85 |
| In which: Operating costs | 4,393,919,087.41 | 4,836,588,741.76 |
| Operating tax and surcharges | 137,567,242.03 | 150,278,107.37 |
| Selling expenses | 2,951,059,287.90 | 3,428,038,993.64 |
| Administrative expenses | 708,729,617.84 | 680,009,158.86 |
| R&D expenses | 1,036,376,310.06 | 1,211,596,866.40 |
| Financial expenses | -105,969,421.63 | -314,423,140.18 |
| In which: Interest expenses | 94,972,898.62 | 106,424,878.84 |
| Interest income | 245,985,558.70 | 373,189,603.11 |
| Add: Other income | 124,184,202.58 | 150,725,832.49 |
| Income from investments (loss is indicated by“-”) | 51,650,239.89 | 58,569,845.80 |
| In which: Income from investments in associates and joint ventures | 34,370,020.06 | 57,873,393.21 |
| Gains from derecognition of financial assets at amortized cost | ||
| Gains from net exposure hedges (loss is indicated by“-”) | ||
| Gains from changes in fair values (loss is indicated by“-”) | -5,736,443.62 | -46,003,628.22 |
| Losses of credit impairment (loss is indicated by“-”) | -797,210.83 | -17,737,505.85 |
| Assets impairment loss (loss is indicated by“-”) | -113,694,072.70 | -108,440,945.45 |
| Gains from disposal of assets (loss is indicated by“-”) | -370,399.04 | -200,478.63 |
| III. Operating profit (loss is indicated by“-”) | 2,832,383,097.69 | 2,696,081,778.73 |
| Add: Non-operating income | 6,920,279.40 | 6,302,873.99 |
| Less: Non-operating expenses | 19,988,508.91 | 23,765,998.31 |
| IV. Total profit (loss is indicated by“-”) | 2,819,314,868.18 | 2,678,618,654.41 |
| Less: Income tax expenses | 385,618,343.11 | 433,823,342.57 |
| V. Net profit (loss is indicated by“-”) | 2,433,696,525.07 | 2,244,795,311.84 |
| (I) Classified by business continuity | ||
| 1. Net profit from ongoing operation (loss is indicated by“-”) | 2,433,696,525.07 | 2,244,795,311.84 |
| 2. Net profit from discontinuing operation (loss is indicated by“-”) | ||
| (II) Classified by ownership | ||
| 1.Net profit attributable to shareholders of the parent (loss is indicated by“-”) | 1,111,560,063.92 | 1,083,649,154.75 |
| 2.Profit and loss of minority shareholders (loss is indicated by“-”) | 1,322,136,461.15 | 1,161,146,157.09 |
| VI. Other comprehensive income, net of tax | -86,688,069.37 | -22,658,520.87 |
| (I) Other comprehensive income attributable to owners of the parent, net of tax | -59,369,859.17 | 1,005,760.40 |
| 1. Other comprehensive income that cannot be reclassified into profit or loss | -58,031,748.84 | -31,488,647.75 |
| (1) Changes from remeasurement of defined benefit plans | ||
| (2) Other comprehensive income that cannot be reclassified into profit or loss under the equity method | ||
| (3) Changes in fair value of investments in other equity instruments | -58,031,748.84 | -31,488,647.75 |
| (4) Changes in fair value of the enterprise's own credit risks | ||
| 2. Other comprehensive income that will be reclassified into profit or loss | -1,338,110.33 | 32,494,408.15 |
| (1) Other comprehensive income that can be reclassified into profit or loss under the equity method | -174,001.08 | 164,225.81 |
| (2) Changes in fair value of other debt investments | ||
| (3) Amount of financial assets reclassified into other comprehensive income | ||
| (4) Provision for credit impairment of other debt investments | ||
| (5) Reserve for cash flow hedges | ||
| (6) Exchange translation differences on financial statements denominated in foreign currencies | -1,164,109.25 | 32,330,182.33 |
| (7) Others | ||
| (II) Other comprehensive income attributable to minority shareholders, net of tax | -27,318,210.20 | -23,664,281.27 |
| VII. Total comprehensive income | 2,347,008,455.70 | 2,222,136,790.97 |
| (I) Total comprehensive income attributable to owners of the parent company | 1,052,190,204.75 | 1,084,654,915.15 |
| (II) Total comprehensive income attributable to minority shareholders | 1,294,818,250.95 | 1,137,481,875.82 |
| Ⅷ. Earnings per share | ||
| (I) Basic earnings per share (RMB/share) | 0.5945 | 0.5682 |
| (II) Diluted earnings per share (RMB/share) | 0.5944 | 0.5663 |
Person-in-charge of theCompany: Zhu Baoguo
Person-in-charge of theCompany's accounting work:
Qiu Qingfeng
Person-in-charge of theaccounting department:
Guo Chenlu
Consolidated Cash Flow Statement
From January to September, 2024Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | First three quarters (January to September) for 2024 | First three quarters (January to September) for 2023 |
| I. Cash flow from operating activities: | ||
| Cash received from sales of goods and rendering of services | 12,943,223,324.92 | 13,510,230,759.20 |
| Tax refunds received | 101,353,328.18 | 141,490,762.85 |
| Other cash received related to operating activities | 422,265,935.11 | 620,955,869.98 |
| Subtotal of cash inflow from operating activities | 13,466,842,588.21 | 14,272,677,392.03 |
| Cash paid for goods and services | 3,827,753,296.70 | 4,573,141,561.87 |
| Cash paid to and on behalf of employees | 1,933,905,112.85 | 1,764,671,591.22 |
| Payments of all types of taxes | 1,480,113,236.04 | 1,416,153,712.56 |
| Other cash paid related to operating activities | 3,611,465,441.56 | 4,058,858,781.68 |
| Subtotal of cash outflow in operating activities | 10,853,237,087.15 | 11,812,825,647.33 |
| Net cash flow from operating activities | 2,613,605,501.06 | 2,459,851,744.70 |
| II. Cash flow from investing activities: | ||
| Cash received from disposal of investment | 684,870,511.47 | 390,344,459.46 |
| Cash received from investment income | 21,390,153.27 | 70,124,524.03 |
| Net cash received from disposal of fixed assets, intangible assets and other long-term assets | 474,130.00 | 8,042,426.01 |
| Net cash received from disposal of subsidiaries and other business units | 8,392,000.00 | |
| Other cash received related to investing activities | 297,590,000.00 | |
| Subtotal of cash inflow from investing activities | 715,126,794.74 | 766,101,409.50 |
| Cash paid for purchase and construction of fixed assets, intangible assets and other long-term assets | 737,034,937.83 | 753,228,828.13 |
| Cash paid for investment | 1,160,648,306.49 | 439,136,113.68 |
| Net cash paid for acquisition of subsidiaries and other business units | 22,461,951.59 | |
| Other cash paid related to investing activities | 1,404,603.34 | 227,027,492.56 |
| Subtotal of cash outflow in investing activities | 1,899,087,847.66 | 1,441,854,385.96 |
| Net cash flow from investing activities | -1,183,961,052.92 | -675,752,976.46 |
| III. Cash flow from financing activities: | ||
| Cash received from capital contribution | 261,660,059.73 | 18,056,784.20 |
| In which: Cash received from investment by minority interests of subsidiaries | 165,101,999.95 | 6,700,000.00 |
| Cash received from borrowings | 3,730,993,152.42 | 3,347,170,168.70 |
| Other cash received related to financing activities | 1,062,615.02 | 20,000,000.00 |
| Subtotal of cash inflow from financing activities | 3,993,715,827.17 | 3,385,226,952.90 |
| Cash repayments of amounts borrowed | 4,293,197,628.28 | 2,592,352,425.04 |
| Cash payments for interest expenses and distribution of dividends or profits | 1,447,407,636.60 | 1,570,166,936.38 |
| In which: Dividends and profit paid minority interests of subsidiaries | 1,007,311,935.18 | 1,120,761,303.69 |
| Other cash payments related to financing activities | 400,728,019.90 | 1,210,358,606.39 |
| Subtotal of cash outflow in financing activities | 6,141,333,284.78 | 5,372,877,967.81 |
| Net cash flow from financing activities | -2,147,617,457.61 | -1,987,651,014.91 |
| IV. Effect of exchange rate fluctuations on cash and cash equivalents | -37,426,542.59 | 71,991,155.94 |
| V. Net increase in cash and cash equivalents | -755,399,552.06 | -131,561,090.73 |
| Add: Opening balance of cash and cash equivalents | 15,340,869,372.73 | 14,178,465,686.40 |
| VI. Closing balance of cash and cash equivalents | 14,585,469,820.67 | 14,046,904,595.67 |
Person-in-charge of theCompany: Zhu Baoguo
Person-in-charge of theCompany's accounting work:
Qiu Qingfeng
Person-in-charge of theaccounting department:
Guo Chenlu
(Ⅲ) Implementation of new accounting standards or interpretations of standards, for the third time from2024 involves adjustments to the financial statements at the beginning of the year
□Applicable √N/A
Hereby the announcement is made.
Joincare Pharmaceutical Group Industry Co., Ltd.
24 October, 2024